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Abstract. We report on a general strategy for engineer- 
ing dominant negative mutations that, in principle, re- 
quires neither extensive structural or functional knowl- 
edge of the targeted protein. The approach consists 
of fusing the lysosomal protease cathepsin B (CB) to 
a subunit of a multimeric protein. The CB fusion 
polypeptide can proteolytically  digest the multimer 
and/or detour the multimer from its usual subcellular 
destination to the lysosome. We first demonstrate the 
general validity of the approach with CB fusion to E. coli 
lacZ, encoding tetrameric 13-galactosidase. Cotransfec- 
tion of NIH 3T3 cells with a vector expressing a CB- 
lacZ fusion inhibits the 13-galactosidase activity pro- 
duced by transfection of lacZ alone. We infer that the 
dominant negative inhibition results from both direct 
proteolysis of the 13-galactosidase tetramer by the fu- 
sion subunit and detour of the tetramer to the lyso- 
some. In a specific application of this strategy, we have 
fused CB to the dimeric bHLH skeletal muscle tran- 
scription factor MyoD. The CB-MyoD fusion protein 
localizes to the cytoplasm, presumably the lysosome, 
demonstrating the dominance of lysosomal localization 
to nuclear localization. The CB-MyoD fusion appears 
to divert homodimerizing native MyoD from its usual 
nuclear destination, consequently inhibiting MyoD- 
mediated transactivation and in vitro differentiation of 
C2C12 myoblasts. Surprisingly, the CB-MyoD fusion 
fails to interact with the bHLH heterodimerization 
partners, El2 and E47, suggesting preferential MyoD 
homodimer formation, at least in the prenuclear cellu- 
lar compartments. 
T 
HE selective suppression  of gene expression  is both 
an experimental tool for defining function and a po- 
tential means to medical therapy. One approach is 
antisense  (for  review  see  Wagner,  1995); another  ap- 
proach is to interfere with the protein product of the gene 
through "dominant negative mutation" of an associating 
protein  (for review  see  Herskowitz, 1987). Designing  a 
dominant negative mutation requires some understanding 
of the structure and function of that protein. In contrast, 
the advantage of antisense is apparent when structural and 
functional information for the gene product is limited. 
We have sought a straightforward strategy for engineer- 
ing dominant negative mutations that, like antisense, po- 
tentially requires minimal knowledge of the gene's struc- 
ture  and  function. We  reasoned  that  for  a  multimeric 
protein,  fusion of one  subunit to  a  lysosomal protease 
could dominantly  inhibit the assembled multimer, and per- 
haps other associating proteins through a combination of 
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proteolysis of the native subunits and/or subcellular diver- 
sion of the multimer to the lysosome. 
Experiments with the cellular CD4 receptor and its HIV 
envelope glycoprotein ligand bear  on  the possibility  of 
achieving dominant negative inhibition by diverting a pro- 
tein from its usual subcellular  trafficking pattern. A CD4 
molecule deleted in the transmembrane and cytoplasmic 
domains is a soluble molecule capable of competitively an- 
tagonizing ligand-receptor interaction (Smith et al., 1987). 
When an endoplasmic reticulum (ER) retention signal is 
fused to the gene encoding this soluble  version of CD4, 
cells expressing the ER-CD4 fusion retain it in the lumen 
of the ER along with the associating  envelope glycopro- 
tein (Buonocore and Rose, 1990). An interesting deriva- 
tive of this approach was developed by Tang and cowork- 
ers (Lin et al., 1993). When the gene encoding the soluble 
CD4 is combined with any of several genes encoding lyso- 
somal proteins, HIV-infected cells expressing  the fusion 
protein can divert, in trans, associating envelope glycopro- 
tein to the lysosome, where it is degraded. 
An open question of cell biology potentially prohibiting 
the adaptation of this strategy to other proteins relates to 
the sequence of events in lysosomal targeting.  In general, 
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bound ribosomes, posttranslationally modified with man- 
nose-6-phosphate in the Golgi, recognized by specific re- 
ceptors, and then incorporated into clathrin-coated vesicles 
eventually routed to the lysosome (for review see Korn- 
feld and Sly, 1995). The opportunities for a lysosomally di- 
rected protein to interact with proteins bound for other 
subcellular  compartments  or  synthesized  on  free  ribo- 
somes might be limited. On the other hand, there is evi- 
dence for alternate pathways to the lysosome, and indica- 
tions that lysosomal proteins can at times be found freely 
soluble in the cytoplasm or elsewhere in the cell (as dis- 
cussed by Kornfeld and Sly, 1995).  The frequency of en- 
counters between proteins predominately localized to the 
lysosome and other subcellular destinations therefore re- 
mains unknown. 
To test the possibility of using fusion with a lysosomal 
protease as a general means of effecting dominant nega- 
tive inhibition,  we have constructed gene fusions to the 
carboxyl terminus of the lysosomal cysteine protease pre- 
procathepsin B (CB).  t We first made a CB fusion with the 
E. coli lacZ gene encoding 13-galactosidase,  a homotetra- 
meric enzyme, and found that its expression inhibits 13-gal- 
actosidase  activity when  cotransfected  into  mammalian 
cells with native lacZ. Both lysosomal routing and an in- 
tact protease active sight  appear required for dominant 
negative inhibition of the ~-galactosidase tetramer assem- 
bled from native and CB-fusion lacZ subunits. As a spe- 
cific application  of this  strategy, we  have constructed  a 
dominant negative version of the skeletal muscle bHLH 
transcription factor MyoD. We find that a CB-fusion with 
MyoD inhibits myogenesis, but achieves the effect through 
homodimerization with MyoD rather  than heterodimer- 
ization with E12 or E47. 
Materials and Methods 
Plasmids 
pCS2+, a simian CMV promoter/enhancer expression vector, has been 
described (Turner and Weintraub, 1994; Rupp and Weintraub, 1994) and 
with the noted derivatives were gifts from D. Turner (Fred Hutchinson 
Cancer  Research  Center  [FHCRC],  Seattle,  WA).  pCS2+CB  and 
pCS2+CB-myc6 were  made  by  PCR  of the  mouse preprocathepsin B 
cDNA of pmCB58 (Chan et al., 1986; a gift of A. Frankfater, Loyola, Chi- 
cago, IL) from bases 35 to 1047 (GenBank M14222) with HindIII and ClaI 
sites incorporated into  the upstream and  downstream primers, respec- 
tively, then ligated in frame, respectively, into the corresponding sites of 
pCS2+  and  pCS2+myc  6,  containing  a  hexameric  myc  epitope  tag. 
pCS2+13gal  encoding E. coli lacZ, and pCS2+NLS-13gal (referred to as 
pCS2+NLS/IacZ in this paper, for consistency), encoding an amino termi- 
nus fusion of the SV40 T-antigen nuclear localization signal with lacZ, 
have been described (Turner and Weintraub, 1994; Rupp and Weintraub, 
1994). pCS2+CB-lacZ was made by ligation of a HindlII-BsaBI fragment 
containing the CB coding sequence of pCS2+CB into the HindlIl/Klenow 
filled-in  BamHI  sites  of  pCS2+~gal,  pCS2+CB-lacZ-HA~  was  con- 
structed by ligation of hexameric influenza virus HA epitope tag from 
pCS2+HA6 (a gift of R. Kopan, Washington University, St. Louis, MO) 
into pCS2 + CB-IacZ. pCS2+NLS-lacZ-myc  6 was constructed by ligating a 
BamHI-XbaI fragment containing the hexameric myc epitope tag from 
pCS2+myc6 into the BgllI and XbaI sites of pCS2+NLS-13gal,  pCS2+ 
myc6-MyoD, a vector containing myc6 epitope-tagged full-length mouse 
MyoD eDNA has been described (Turner and Weintraub, 1994; Rupp and 
Weintraub,  1994).  pCS2+CB*lacZ,  containing a  frame shift mutation 
leading to termination codons between the CB and tacZ domains was con- 
1. Abbreviation used in this paper: CB, protease cathepsin B. 
structed by ligation of a HindlII-ScaI fragment of CB into the HindlII/ 
Klenow filled-in BamHI  sites of pCS2+13gal,  pCS2+CB(C108S)-IacZ, 
containing a TGT to AGC substitution at codon 108 of the CB active site, 
resulting in replacement of cysteine by serine, was constructed by oligonu- 
cleotide cassette mutagenesis spanning from the BanII to Bsml site of the 
coding sequence of pCS2+CB, pCS2+ CB-myc~-MyoD was made by ligat- 
ing the EcoRI-XbaI fragment of pCS2 + mycr-MyoD into the correspond- 
ing sites of pCS2+CB-Myc6, pCS2+CB*MyoD, a  control plasmid that 
contains a stop codon and lacks the myc epitope tag between the two 
domains,  was  constructed  by  ligafing  the  ClaI-XbaI  fragment  of 
pCS2+MyoD into pCS2+CB, identical to pCS2+CB-myc6, except for the 
absence of the myc epitope tag. pCS2+CB-MyoD, also lacking the myc 
epitope tag but containing a continuous open reading frame of the fused 
domains,  was  constructed  by  removing  the  stop  codon  of  pCS2+ 
CB*MyoD with ClaI digestion, Klenow fill-in, and self-ligation, pCS2+ 
CB-MyoDAHLH,  pCS2+CB-myc6-MyoDAHLH,  pCS2+CB-MyoDAb, 
and pCS2+CB-mycs-MyoDAb were constructed by PCR amplification of 
mouse  MyoD  (using primers  corresponding to  sequence  160-176 and 
1116-1099 of GenBank M18779 and incorporating EcoRl and XbaI sites, 
respectively) from the plasmids pEMSV-MyoDAHLH(143-162), contain- 
ing a deletion of part of the loop and helix 2, and pEMSV-MyoDAb(102- 
114), containing a deletion of part of the basic region, (Davis et al., 1990; 
gifts of the late H. Weintraub, Fred Hutchinson Cancer Research Center), 
respectively, with cloning into the corresponding sites of pCS2+CB and 
pCS2+CB-myc6, respectively, pCS2+CB-MyoDAC was constructed by 
PCR amplification of mouse MyoD (using primers corresponding to se- 
quence 160-176 and 657-640 and incorporating EcoRI and XbaI sites, re- 
spectively) from the plasmid pEMSV-MyoD(TM167), containing a termi- 
nation codon substituted for residue 167 (Weintraub et al., 1991; a gift of 
H. Weintraub, Seattle, WA), with cloning into the corresponding sites of 
pCS2+CB.  (pCS2+CB-MyoDAC(167)  also  contains  myc6  and  HA  6 
epitope tags, although these features were not used for the present stud- 
ies.) pSV-myc6-E12, an expression vector for human El2 eDNA was a gift 
of Y. Zhuang (Duke, Durham, NC). pCS2+CB-myc6-E12 and pCS2+CB- 
myc6-E47 were constructed by PCR amplification of human El2 and E47 
from pEMSV-E12 and pEMSV-E47 (gifts of H. Weintraub) at positions 
10-27 and 1336-1218  (with respect to the El2 sequence of Murre et al., 
1989a) with the incorporation of EcoRI and XbaI sites, respectively, and 
cloning  into  the  corresponding sites  of  pCS2+CB-myc~.  EMSV-E12- 
MyoD(BJ) (Davis and Weintraub, 1992), a construct containing a MyoD 
basic DNA-binding domain fused to the El2 HLH dimerization domain, 
was a gift of H. Weintraub. pD-4R-13-gal,  a reporter vector containing 4 
E-boxes and a minimal ItSV TK promoter, is identical to the p4R-cat re- 
porter described by Weintraub et al., (1990),  except for replacement of 
the cat reporter gene with 13-galactosidase,  that which was a gift from S. 
Tapscott  (Fred Hutchinson Cancer Research Center).  pEMSVscribe 
expression vector for mouse MyoD cDNA (pEMSV-MyoD) has been de- 
scribed (Davis et al., 1987) and were gifts of H. Weintraub. pEMSV-CB- 
MyoD was constructed by ligating a Klenow filled-in fragment of CB-MyoD 
from pCS2 + CB-MyoD into the SmaI site of pEMSVscribe. Plasmids were 
purified on columns (Qiagen, Chatsworth, CA). 
Cell Culture and Transfection 
Hybridoma supernatants were a  gift of H. Weintraub and P.-F. Cheng 
(FHCRC). Mouse NIH 3T3 cells (Amer. Type Culture Collection [ATCC], 
RockviUe, MD) were grown in DMEM with 10% bovine calf serum, and 
mouse C2C12 myoblasts (ATCC) were grown in DMEM with 15% FCS. 
Penicillin/streptomycin  (1%) was added to the media. Myoblast differenti- 
ation was induced 24 h after transfection by placing cells in DMEM with 
2% heat inactivated horse serum for 48 h. 5 ×  105 cells were seeded onto 
60-ram plates and transiently transfected ~12 h later by CaPO  4 precipita- 
tion using Hepes buffered saline (Kriegler, 1990) with 10 p~g DNA (unless 
stated otherwise). The CaPO4/DNA precipitate remained on the cells for 
17 h, when the cells were fed with fresh media. When used, N1-LC1 was 
added to the media at a concentration of 10 mM at the conclusion of trans- 
fection. 
Immunofluorescent Staining and Photomicroscopy 
48 h following transfection, cells were fixed for 3 rain with 50% methanol/ 
50% acetone, and incubated for 60 min at room temperature with the ap- 
propriate antibody at the indicated dilution in PBS: 1:3 of 9E10 anti-myc 
epitope  mouse  hybridoma  supernatant  (as  referenced in  Turner  and 
Weintraub, 1994),  undiluted 5.8 anti-MyoD mouse hybridoma superna- 
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1:200 rabbit polyclonal anti-MyoD (Tapscott et al., 1988; a gift of H. Wein- 
traub and L. Snider, FHCRC),  1:200  rabbit polyclonal anti-HA epitope 
(BABCO),  and  1:200  rabbit  polyclonal  anti-skeletal  myosin  (Sigma 
Chemical Co., St. Louis, MO). Secondary detection was by incubation for 
30 min at room temperature with 20 p,g/ml fluorescein- or rhodamine-con- 
jugated, noncross-reactive, donkey anti-mouse or anti-rabbit, respectively, 
antibodies (Jackson Labs., West Grove, PA). Nuclei were counterstained 
by incubation for 3 min in 0.5 p~g/ml DAPI in PBS. Epifluorescence and 
phase contrast photomicroscopy was performed on a  Zeiss Photomicro- 
scope III with 45-s exposure on Kodak Ektachrome P1600 film and pro- 
cessed by E6 protocol with I stop push. Transparencies were scanned onto 
a  Kodak Photo CD  and composited with Adobe  Photoshop (to  adjust 
size, brightness, and contrast) and Adobe Illustrator software for the Mac- 
intosh with output to a dye sublimation printer. 
Cell Extracts and [3-Galactosidase Assay 
Cells were harvested for extraction 48 h following transfection. Whole cell 
extracts were made by freeze-thaw lysis as described (Sambrook et al., 
1989).  Nuclear  and  cytoplasmic  extracts  were  prepared  as  described 
(Schreiber et al., 1989): the cells were lysed with NP-40 and the nuclei salt- 
extracted in the presence of the protease inhibitors I mM PMSF, 1% (vol/ 
vol) aprotinin, and 10 ~g/ml Mg-132 (Myogenics, Cambridge, MA). 13-Galac- 
tosidase assay was performed on ONPG substrate with spectrophotomet- 
ric quantification of activity as described (Sambrook et al., 1989). Each ex- 
periment was performed in duplicate or triplicate, repeated 3 to 5 times on 
different days, and a standard error of the mean calculated. 
DNA Binding Assays 
In vitro transcription and translation was performed using the TNT cou- 
pled reticulocyte lysate system with the T3 RNA polymerase following the 
manufacturer's instructions (Promega,  Madison, WI).  All gene fusions 
were  moved into  the pEMSV-scribe vector (Davis et  al.,  1987)  as the 
source of the DNA programming the reaction. Translation was verified by 
parallel reactions performed with [35S]methionine with size-resolution of 
the  products  by  SDS-PAGE  and  autoradiography  (not  shown). DNA 
binding assays were performed as described by Davis et al. (1990) using 
the MCK "R" enhancer 25-bp double-stranded oligonucleotide with the 
following modifications: a total of 4 ~l of in vitro synthesized protein was 
used for each binding assay; proteins were incubated for 90 rain at 30°C 
before  adding the  DNA  binding cocktail;  binding reactions were  per- 
formed for 45 min at 25°C. 
Results 
CB-lacZ Associates with lacZ 
E. coil lacZ transfected into mammalian cells produces 
13-galactosidase  that  normally is  cytoplasmically soluble 
(Sambrook et al., 1989). To determine the subcellular lo- 
calization and activity of a polypeptide encoded by a gene 
fusion of the lysosomal cysteine protease preprocathepsin 
B with lacZ (CB-lacZ), we first transfected an expression 
vector encoding this chimera into NIH 3T3 cells. Immuno- 
fluorescent staining with 13-galactosidase  antibodies reveals 
that  CB-lacZ is cytoplasmically distributed,  in a  perinu- 
clear granular pattern consistent with lysosomal localiza- 
tion (not shown, but see below). XGAL staining and an 
assay of [3-galactosidase activity of crude cell extracts on 
ONPG substrate  are both negative (not shown). In con- 
trast, native lacZ gives diffuse cytoplasmic staining with 
~-gatactosidase  antibodies  and  confers  positive  XGAL 
staining and easily detectable activity in crude cell extracts 
(not shown and Sambrook et al., 1989). We conclude that 
CB-lacZ has an abnormal subcellular distribution and fails 
to produce detectable [3-galactosidase activity. 
To determine if CB-lacZ and native lacZ subunits could 
physically associate, we tested the effect of simultaneous 
expression of the two polypeptides. Equal quantities of ex- 
pression vectors encoding both sequences were cotrans- 
fected into NIH 3T3 cells. To differentiate the two poly- 
peptides,  CB-lacZ  was  epitope  tagged  with  a  carboxyl 
terminus hexameric influenza virus hemagluttin tag (HA6), 
to produce CB-IacZ-HA6, while the native lacZ was epi- 
tope tagged with a hexameric myc epitope tag (myc6) at its 
carboxyl terminus, to produce lacZ-myc6. We were unable 
to discern a difference in staining pattern when cells trans- 
fected with both constructs were simultaneously immuno- 
fluorescently stained with antibodies directed against both 
epitope tags (not shown). 
We judged that it would be difficult to discriminate be- 
tween diffuse cytoplasmic staining and a lysosomal stain- 
ing pattern. To therefore make any effects on subcellular 
redistribution more pronounced, we added an SV40 T-anti- 
gen nuclear localization signal  (NLS) to the native lacZ 
subunit, to produce NLS-lacZ-myc6. (NLS-lacZ-myc6 results 
in nuclear localized [3-galactosidase as judged by immuno- 
fluorescent staining with either myc epitope antibody or 
[3-galactosidase  antibodies  or XGAL staining  [Rupp  and 
Weintraub, 1994; see the following].) Transient cotransfec- 
tion of equal quantities of expression vectors for both con- 
structs into NIH 3T3 cells with simultaneous immunofluo- 
rescent  staining  with  mouse  monoclonal  myc  epitope 
antibody (and secondary detection with fluorescein-conju- 
gated goat anti-mouse serum) and rabbit polyclonal HA 
antibody (and secondary detection with rhodamine-conju- 
gated goat anti-rabbit serum) reveals that both the CB- 
lacZ-HA6 and the NLS-lacZ-myc6 polypeptides are distrib- 
uted in the cytoplasm in many of the cells (Fig. 1, top row). 
(A similar pattem was observed by staining with 13-galac- 
tosidase antibody, not shown, confirming that the localiza- 
tion  of the  epitope  tag  is  the  same  as  the  rest  of the 
polypeptide.) In contrast, control cotransfection of vectors 
expressing NLS-lacZ-myc6 with CB-HA6 fails to result in 
the redistribution of nuclear-localized lacZ (Fig. 1, middle 
row). (Note that not all cells express both plasmids.) We 
conclude that CB-lacZ-HA6 is able to effect the nuclear to 
cytoplasmic redistribution of NLS-lacZ-myc6, presumably 
through the assembly of a 13-galactosidase  tetramer com- 
posed of both types of subunits. 
CB-lacZ Inhibits fl-Galactosidase Activity 
We next tested whether cotransfection with CB-lacZ was 
capable of inhibiting the [3-galactosidase activity that re- 
sults from transfection with NLS-IacZ (Fig. 2 A). A 2:1 mass 
ratio of plasmid DNA encoding CB-lacZ and NLS-lacZ, 
respectively, were transiently cotransfected into NIH 3T3 
cells. Whole cell, nuclear, and cytoplasmic extracts were pre- 
pared and [3-galactosidase activity was measured by spec- 
trophotometric assay on ONPG substrate. Cotransfection 
with CB-IacZ, but not the control plasmid CB*IacZ con- 
taining a termination codon (*) between the two domains, 
inhibits  about half of the  [3-galactosidase activity in the 
whole cell extracts as well as in the nuclear and cytoplas- 
mic fractions. (Some [3-galactosidase activity presumably 
"leaks" into the cytoplasm.) Similar results  (not shown) 
were obtained with  cotransfection of CB-IacZ and lacZ 
(without the NLS). 
Li et al. Dominant Negative Mutation  1045 Figure 1.  CB-IacZ-HA6 redistributes  NLS-lacZ-myc6, but not in the presence of NH4C1. CB-lacZ-HA  6 or the control construct CB-HA6 
were transiently  cotransfected with NLS-lacZ-myc 6 at a ratio of 5 i~g:5 I~g into NIH 3T3 ceils, and simultaneously immunofluorescently 
stained with 9El0 mouse monoclonal anti-myc epitope with secondary fluorescein detection and rabbit polyclonal anti-HA epitope with 
secondary rhodamine detection in the absence or presence (for experiments with CB-lacZ-HA6 only) of the lysosomal transport inhibi- 
tor NHaCI. Nuclei were DAPI counterstained. 
Dominant Negative Inhibition Requires 
Lysosomal Routing 
We  sought  to  determine  if lysosomal localization  is  re- 
quired  for the  dominant  negative inhibition.  The most 
direct approach would be to delete the lysosomal localiza- 
tion signal from the  CB  coding sequence.  A  discrete ly- 
sosomal localization signal, however, has yet to be defined 
for CB (Sloane, B., personal communication). An alterna- 
tive experiment is based on the observation that treatment 
of cells with NH4C1 blocks lysosomal targeting by inhibi- 
tion of the mannose-6-phosphate dependent pathway (as 
reviewed  in  Kornfeld  and  Sly,  1995).  We  repeated  the 
above cotransfection experiments in the presence of NI-I4C1. 
Simultaneous immunofluorescent staining (Fig. 1, bottom 
row)  shows  that  cotransfection  of  CB-IacZ-HA6  with 
NLS-lacZ-myc6 in the presence of NHaCI fails to result in 
the cytoplasmic redistribution of NLS-IacZ; in fact, the re- 
verse situation  occurs,  and  the  CB-lacZ-HA6 appears to 
now redistribute from the cytoplasm to the nucleus under 
these  conditions.  Assay  of  13-galactosidase  activity  con- 
firms that CB-IacZ no longer achieves dominant negative 
inhibition  in  the presence of NHaCI (Fig. 2  B).  We con- 
clude that  lysosomal localization of the  CB  fusion is re- 
quired for dominant negative inhibition. 
Dominant Negative Inhibition Requires CB 
Protease Activity 
We next addressed if lysosomal localization alone is suffi- 
cient to achieve dominant negative inhibition, or whether 
the protease function of CB contributes to inhibition.  CB 
protease activity requires an active site cysteine; mutation 
to  serine  results  in  an  inactive  enzyme  (Rowan  et  al., 
1992).  We mutated the CB active site in CB-lacZ replacing 
the  cysteine with  a  serine,  to  produce  CB(C108S)-IacZ. 
The mutation has no effect on the subcellular distribution 
of the fusion protein, as determined by immunofluorescent 
staining with an epitope tagged derivative (not shown). The 
mutation did impair the ability of the fusion protein to in- 
hibit 13-galactosidase  activity when cotransfected with NLS- 
lacZ in NIH 3T3 cells (Fig. 2  C). We conclude that pro- 
teolysis of the substituted tetramer by CB also contributes 
to the mechanism of dominant negative inhibition. 
At Least Two Subunits of the ~-Galactosidase Tetramer 
Must Be Substituted 
We next asked how many subunits of the tetramer must be 
substituted with the CB fusion polypeptide in order to in- 
active the holoenzyme. This was addressed by titrating the 
The Journal of Cell Biology,  Volume 135, 1996  1046 Figure 2.  (A) Quantification  of inhibition  of 13-galactosidase activity. NIH 3T3 cells were transiently  transfected with the indicated 
quantities  of vectors and whole cell, nuclear, and cytoplasmic extracts were prepared. 13-Galactosidase activity was assayed spectropho- 
tometrically on ONPG substrate and reported as normalized values. (B) No inhibition  of 13-galactosidase activity by CB-lacZ in the 
presence of the lysosomal transport inhibitor NHgC1. 13-Galactosidase activity was assayed in whole cell extracts and normalized values 
are shown. (Overall 13-galactosidase  activity, even produced by transfection  of NLS-lacZ alone, was reduced in the presence of NH4C1.) 
(C) No inhibition  of 13-galactosidase activity by CB-IacZ(C108S) in which the active site cysteine has been mutated. The conditions  are 
as described  above. 
ratio  of  CB-lacZ  to  NLS-lacZ  expression  vector  trans- 
fected into NIH 3T3 cells and determining the shape of the 
inhibition curve. The possible combinations and permuta- 
tions of tetramers resulting from the two types of subunits 
represent a binomial expansion (Fig. 3 A). Assuming that 
the concentration of each subunit is proportionate to the 
amount transfected, that the probability of association of 
the two subunits is proportionate to their respective con- 
centrations,  and  that  13-galactosidase  activity  is  propor- 
tionate to the concentration  of active tetramer; then, the 
indicated equation  (Fig. 3  B), derived from the binomial 
expansion,  predicts  resulting  13-galactosidase  activity for 
any value of r, where r is an integer equal to the number of 
CB-lacZ subunits tolerable in an active tetramer (Fig. 3 C). 
(Note that an additional, unproven assumption is that the 
stoichiometry of the  13-galactosidase enzyme remains un- 
changed when CB-lacZ subunits are incorporated into the 
multimer.) Obviously, if r  =  4 (that is, (CB-lacZ)4 retains 
activity), then 13-galactosidase activity additively increases 
as more CB-lacZ is transfected into the  cells (Fig.  3 D). 
Similarly, note that if r  =  3  or r  =  2  (that is, a  tetramer 
substituted  with  three  or  two  CB-lacZ subunits,  respec- 
tively,  retains  activity),  then  inhibition  also  cannot  be 
achieved.  The  results  of  the  titration  experiment  are 
shown in Fig. 3 E. The best curve fit of the data was ob- 
tained using the indicated equation at values of r  =  1 with 
a  relative dissociation constant  k  for CB-lacZ of 0.59  _ 
0.08.  We conclude that there is tolerance for one CB-lacZ 
subunit  in an active tetramer, but that a  tetramer substi- 
tuted with two or more CB-lacZ subunits is inactive. We 
also conclude that steric hindrance from the CB domain in 
the CB-lacZ polypeptide contributes little to inhibition, as 
the calculated relative dissociation constant for CB-lacZ is 
near unity. 
Cis Dominance of  Lysosomal Routing to Nuclear 
Localization for MyoD 
As a first application of this method of dominant negative 
mutation, we investigated the subcellular distribution and 
dimerization properties of MyoD. We first determined if 
the lysosomal targeting signal could function in dominance 
to  nuclear  localization  signals  (encoded  in  two  motifs 
within the MyoD bHLH [Vandromme et al., 1995]) when 
present together on a single polypeptide. This is of impor- 
tance to the premise of this strategy that CB fusion can be 
used as a  dominant negative inhibitor  in  the  absence of 
structural  and  functional  knowledge  of the  gene  to  be 
studied.  If the  lysosomal localization signal does not  act 
dominantly to other subcellular localization signals when 
present  together  on a  single polypeptide, then these  sig- 
nals would first have to be identified and deleted for the 
method to work. We constructed an epitope tagged fusion 
of CB with the full-length MyoD protein coding sequence, 
CB-myc6-MyoD. As  shown by immunofluorescent stain- 
ing for the myc epitope of transiently transfected mouse 
NIH 3T3 cells (lacking expression of endogenous MyoD) 
in Fig. 4, myc6-MyoD (top row) appears nuclear, CB-myc6 
(bottom row) appears  cytoplasmic  (presumably  lysoso- 
mal), and CB-myc6-MyoD (middle row) is similarly cyto- 
plasmic, indicating the c/s dominance of lysosomal target- 
ing. (Simultaneous staining with MyoD antibodies results 
in  an  identical  pattern,  not  shown,  indicating  that  the 
staining  pattern  is unlikely to  be the  result of a  protein 
processing event that has caused the epitope tag to dissoci- 
ate from the MyoD domain.) A corroborating result is that 
the SV40 T-antigen nuclear localization signal fused amino 
terminal  to  epitope  tagged  preprocathepsin  B  also  pro- 
duces a similar pattern of cytoplasmic staining (not shown). 
Although  we  cannot  be certain  that  the  CB-fusion  pro- 
Li et al. Dominant Negative Mutation  1047 Figure 3.  (A) Possible combinations  and permutations of native and CB-fusion lacZ subunits in the tetramer. (B) Equation predicting 
13-galactosidase inhibition for differing number of CB-substituted  subunits tolerable in the tetramer (r). (C) Graphical definition of r as 
the number of CB-substituted  subunits tolerable in the tetramer. An "X" indicates an inactive tetramer. (D) Predicted  shape of the ti- 
tration curve for differing r values. (E) Titration experiments.  5 I~g of NLS-lacZ expression vector were transiently transfected into NIH 
3T3 cells with the indicated quantity of CB-lacZ expression vector (0-20 p~g). [3-Galactosidase activity was assayed from whole cell ex- 
tracts and plotted relative to the quantity of vector added.  Optimal values of r and k were determined by curve-fitting  following the 
Davidon-Fletcher-Powell  algorithm,  using MacCurveFit  software  (Kevin Raner Software, Victoria, Australia).  The correlation coeffi- 
cient R  2 for quality of fit is 0.74. The experiment was performed once with integral quantities of CB-lacZ expression vector from 0 to 16 
o.g and repeated in duplicate on a different day for each of integral quantities of vector from 0 to 20 ~g. 
teins are located in the lysosome, the lysosomal localiza- 
tion signal, when present on the same polypeptide with a 
nuclear localization signal, does appear to result in at least 
the cytoplasmic redistribution of a nuclear protein. 
Trans-Diversion of  MyoD to the Cytoplasm 
MyoD forms homodimers and also forms heterodimers with 
the  ubiquitously  expressed and  alternately spliced prod- 
ucts, El2 and E47, of the E2A gene (as reviewed by Mtin- 
sterberg and Lassar, 1994;  Edmondson and Olson, 1993). 
We next tested if CB-MyoD could divert homodimerizing 
native MyoD away from the  nucleus  (Fig.  5 A).  Double 
immunofluorescent staining for the myc epitope tag and 
MyoD  reveals  that  transient  cotransfection  of untagged 
CB-MyoD with myc6-MyoD (Fig. 5 A, top row) results in 
the redistribution of some fraction of myc epitope-tagged 
MyoD to the cytoplasm in many of the cells. Cotransfec- 
tion with the control construct CB*MyoD, identical except 
for a stop codon between the two domains, has no effect 
on MyoD nuclear localization (Fig. 5 A, second row). To 
verify that dimerization with CB-MyoD is required to re- 
direct the native MyoD, we constructed CB-MyoD fusions 
in which we deleted either the HLH dimerization domain 
or the basic DNA-binding region of MyoD. (Neither Myo- 
DAHLH nor MyoDAb are active; MyoDAHLH does not 
form dimers while  MyoDAb forms dimers but  does  not 
bind DNA [Davis et al.,  1990].)  Cotransfection with CB- 
MyoDAHLH, in which a portion of the HLH domain has 
been deleted, has no effect on MyoD nuclear localization 
(Fig. 5 A, third row) whereas CB-MyoDAb, in which part 
of the basic region has been deleted, retains the ability to 
redirect native MyoD to the cytoplasm (Fig. 5 A, bottom 
row). Surprisingly, myc epitope-tagged El2 remains exclu- 
sively nuclear in  the  presence of cotransfection with the 
untagged CB-MyoD chimera (Fig. 5 B, top row). Similar 
results were obtained with E47 (not shown).  Conversely, 
cotransfection of CB-myc6-E12 with MyoD also failed to 
divert MyoD from the nucleus (Fig. 5 B, bottom row). 
In Vitro Dimer Formation by CB-MyoD with 
MyoD or El2 
A  potential explanation for why CB-MyoD fails to dem- 
onstrate intraceUular interaction with E12 and E47 may be 
that the dimerization potential of the CB fusion protein is 
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somal  localization  signal to 
MyoD  nuclear  localization. 
Plasmids expressing the indi- 
cated  epitope-tagged  pro- 
teins  were transiently  trans- 
fected into NIH 3T3 cells and 
immunofluorescently  stained 
with mouse monoclonal 9E10 
anti-myc  epitope  with  sec- 
ondary fluorescein detection. 
Nuclei were DAPI counter- 
stained. 
altered. To test this, we performed electrophoretic mobil- 
ity shift assays using an E-box DNA probe and in vitro 
synthesized proteins. In agreement with prior observations 
(Davis et al., 1990), we find that MyoD (Fig. 6, lane 2) or 
E12  bind  DNA  (Fig.  6,  lane  3)  individually,  but,  when 
combined, bind DNA more efficiently (Fig. 6, lane 4). Be- 
cause the shifted complex migrates to a position interme- 
diate between that of either MyoD or E12 alone, these re- 
sults  have been  taken  as  evidence that  the  preferential 
DNA-binding species is a MyoD/E12 heterodimer (Davis 
et  al.,  1990).  In  contrast with  MyoD, we  find  that  CB- 
MyoD fails to bind DNA by itself (Fig. 6, lane 1). When 
CB-MyoD is  combined with E12  (Fig.  6,  lane 5),  DNA 
binding is increased, in comparison to E12 or MyoD alone, 
just as it is with native MyoD. Additionally, we note that 
the presumed CB-MyoD/E12 heterodimer migrates to  a 
position between that of the E12 complex alone and the 
MyoD/E12 complex, confirming that the synergystic effect 
is  achieved  through  heterodimerization with  CB  fusion 
protein. We conclude that, although CB-MyoD is incapa- 
ble of binding DNA by itself, it retains the ability to form 
DNA-binding dimers with native E12. Therefore, the fail- 
ure to observe in vivo interaction between CB-MyoD and 
E12 does not result from artifactual changes in dimeriza- 
tion capability. 
Inhibition of C2C12 Myoblast Differentiation 
We then determined whether the CB-myc6-MyoD chimera 
could  inhibit  myoblast  differentiation  in  vitro.  Mouse 
C2C12 myoblasts, which endogenously express MyoD, were 
transfected with CB-myc6-MyoD, CB-myc6, or myc6-MyoD, 
serum-starved to induce differentiation, and then doubly 
immunofluorescently stained with antibodies against  the 
epitope  and  the  differentiation marker  skeletal  myosin 
(Fig.  7  A).  The  transfected cells  are  distinguishable  by 
their staining with the anti-epitope antibody. Differentia- 
tion is evident by myosin expression and the formation of 
multinucleated  myotubes.  After  transfection  with  CB- 
myc6 (Fig. 7 A, top row), the majority of myc epitope posi- 
tive cells (72%, Fig. 7 B) have differentiated as judged by 
their formation of myosin positive, multinucleated myo- 
tubes.  Differentiation is  accelerated  in  cells  transfected 
with myc6-MyoD (Fig. 7 A, bottom row), as almost all the 
myc epitope positive cells were fused in myosin positive 
myotubes (92%, Fig. 7  B).  Differentiation is reduced in 
cells transfected with  CB-myc6-MyoD (Fig.  7  A, middle 
row),  as few myc epitope positive cells (22%,  Fig.  7  B) 
were fused in myosin positive myotubes. As a  definitive 
control, we also tested for an inhibitor effect of CB-MyoD- 
myc6-AHLH (Fig.  7  C,  top  row)  and  CB-myc6-MyoDAb 
Li et al. Dominant  Negative  Mutation  1049 Figure 5.  (A) CB-MyoD redistributes  epitope-tagged MyoD to the cytoplasm. Plasmids expressing the indicated  epitope-tagged pro- 
teins were transiently cotransfected with untagged CB-MyoD at a ratio of 5 p.g:5 Ixg into NIH 3T3 ceils, and simultaneously immunoflu- 
orescently  stained  with 9El0 mouse monoclonal anti-myc epitope with  secondary fluorescein  detection and rabbit polyclonal  anti- 
MyoD with secondary rhodamine detection.  Nuclei were DAPI counterstained.  (B) CB-MyoD fails to redistribute  epitope-tagged El2 
and epitope-tagged E12-CB fails to redistribute untagged MyoD. The plasmids were transfected and cells stained as above. (Note that 
for the experiment of the bottom row, in contrast to those of the first five rows of the figure, the 9El0 mouse monoclonal anti-myc 
epitope detects the CB-fusion protein while the rabbit polyclonal anti-MyoD detects the target protein being tested for redistribution.) 
(Fig.  7  C, bottom row).  Of the  two, only CB-myc6-Myo- 
DAb inhibited differentiation (52% differentiation vs 18% 
differentiation, respectively, Fig. 7 B), confirming that the 
dominant negative effect is mediated through HLH region 
dimerization but unaffected by the presence of the DNA- 
binding basic region.  We  also found that  the  CB-MyoD 
chimera  inhibits  myogenic conversion  of NIH 3T3  cells 
when cotransfected with MyoD (not shown). In agreement 
with the previous results, neither CB-myc6-E12 (Fig. 7 D, 
top row) nor CB-myc6-E47 (Fig. 7 D, bottom row) inhibits 
differentiation, as the expression of these transfected chi- 
meras  is  largely found  in  differentiated  myotubes  (68% 
and 76%, respectively, Fig. 7 B). 
To confirm that the inhibition of differentiation by the 
CB-fusion results from direct inhibition of MyoD, we con- 
structed CB-MyoDAC, in which the carboxyl terminus of 
MyoD  has  been  deleted  (beginning  at  amino  acid  167). 
Removal of this portion of MyoD has little effect on activ- 
ity (Weintraub et al., 1991), but the deleted carboxyl ter- 
minus does contain an epitope (spanning from amino acids 
170-209)  recognized by the  MyoD  monoclonal  antibody 
5.8  (Dias  et  al.,  1992).  In  C2C12  myoblasts transfected 
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Figure 6.  Electrophoretic mobility  shift  assay with  CB-MyoD. 
The indicated  proteins were synthesized in vitro and tested for 
their ability  to shift  an E  box-containing 32p-labeled double- 
stranded oligonucleotide probe, as shown in this autoradiogram. 
with CB-MyoDAC, it should be possible by immunofluo- 
rescent  staining  to  distinguish  the  endogenous  MyoD 
(which is detectable both with monoclonal 5.8 and poly- 
clonal anti-MyoD) from the CB-MyoDAC (which should 
be detectable with the polyclonal antibody, but not 5.8). 
Transfection of CB-MyoDAC into NIH 3T3 cells (Fig. 7 E, 
top  row),  which do not express endogenous MyoD, con- 
firms that the fusion protein can be immunofluorescently 
stained with the polyclonal MyoD antibody (here detected 
secondarily with rhodamine), but not the 5.8 monoclonal 
antibody (here detected secondarily with fluorescein). CB- 
MyoDAC was transfected into C2C12 myoblasts, serum- 
starved  to  induce  differentiation,  then  simultaneously 
stained  with  polyclonal antibody to  MyoD  and  the  5.8 
monoclonal antibody (with secondary rhodamine and flu- 
orescein  detection,  respectively). As  shown  in  Fig.  7  E 
(bottom row),  the transfected cells are easily distinguish- 
able  using the polyclonal MyoD antibody on account of 
the  bright,  cytoplasmic  staining  pattern.  Staining  with 
monoclonal  antibody 5.8  confirms that  the  endogenous 
MyoD is redistributed to the cytoplasm in the cells trans- 
fected with CB-MyoDAC. 
Furthermore, most of the cells transfected with CB-Myo- 
DAC appear mononuclear (~80%), consistent with their 
failure to differentiate, presumably as a consequence of in- 
hibition of MyoD. 
Inhibition of  MyoD trans-Activation of  an E-box 
Containing Reporter 
To confirm direct inhibition of MyoD trans-activation,  we 
tested (Fig. 8) the ability of the CB-MyoD fusion to di- 
rectly inhibit trans-activation  of a reporter (containing the 
minimal  "4R"  enhancer  (Weintraub  et  al.,  1990),  com- 
posed  of four catenated MyoD E-box DNA  sequences, 
and the thymidine kinase basal promoter). Under the tran- 
sient  assay  conditions  employed,  cotransfection  with 
MyoD results in  about a  threefold induction of [3-galac- 
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tosidase  activity  (lane  D)  when  normalized  to  control 
cotransfection with an empty expression vector (lane A). 
(Note that in order to accommodate an excess of the CB- 
MyoD expression vector, we have reduced the quantity of 
the  MyoD expression vector compared to  that typically 
used  in  assays producing greater levels  of induction by 
MyoD (see for example, Weintraub et al., 1991).)  MyoD 
activation of 4R is inhibited by the addition of CB-MyoD 
in a dose-dependent manner (lanes E  and F), but it is not 
inhibited  by  the  addition  of the  stop  codon-containing 
control CB*MyoD (lanes G and H). Under the conditions 
of lane F, CB-MyoD abolishes trans-activation by MyoD. 
Not only does CB-MyoD alone fail to function as an acti- 
vator (lane B), but it also modestly suppresses basal activity 
of the reporter (compared to control lane C), conceivably 
through inactivation of interacting constitutive transcrip- 
tion factors. In agreement with the colocalization data of 
Fig. 2, the CB-MyoD chimera does not inhibit the activity 
of E12-MyoD(BJ)  (Davis  and Weintraub,  1992),  a  con- 
struct  containing  a  MyoD  basic  DNA-binding  domain 
fused to the El2  HLH dimerization domain, suggesting 
that the two do not interact (lanes l-K). Taken together 
with the previous results, we conclude that CB-MyoD in- 
hibits myoblast differentiation by interfering with the tran- 
Li et al. Dominant Negative Mutation  1053 Figure 7.  (A) CB-myc6-MyoD inhibits myoblast differentiation.  Plasmids expressing the indicated proteins were transiently transfected 
into mouse C2C12 myoblasts and serum starved to induce  differentiation.  The cells were then simultaneously  immunofluorescently 
stained  with 9El0 mouse monoclonal anti-myc epitope with secondary fluorescein  detection,  to identify transfected cells, and rabbit 
polyclonal anti-skeletal myosin with rhodamine detection, to distinguish differentiated myotubes. Nuclei were DAPI counterstained.  Rep- 
resentative results are shown. (B) Quantification of differentiation for the experiments reported in this figure. 50 cells staining posi- 
tively with anti-myc epitope were randomly examined; the percentage that are myosin positive myotubes with three or more nuclei is re- 
ported. (C) CB-myc6-MyoDAHLH does not inhibit differentiation while CB-myc6-MyoDAb does. Transfection and staining were as 
above. (D) CB-myc6-E12 and CB-myc6-E47 do not inhibit differentiation.  Transfection and staining were as above. (E) Redistribution 
of endogenous MyoD demonstrated with CB-MyoDAC, deleted in the epitope recognized  by the 5.8 mouse monoclonal anti-MyoD. 
NIH 3T3 cells, which lack endogenous MyoD expression,  and C2C12 myoblasts, which express endogenous MyoD, were transiently 
transfected with the construct  and simultaneously  stained with the rabbit polyclonal anti-MyoD with secondary rhodamine detection, 
which recognizes both endogenous MyoD and the transfected CB-fusion, and the 5.8 mouse monoclonal anti-MyoD with secondary flu- 
orescein detection,  which recognizes endogenous MyoD, but not the transfected CB-fusion. The C2C12 cells were serum-starved to in- 
duce differentiation  following transfection.  Nuclei were DAPI counterstained. 
scriptional activation of native MyoD independently of as- 
sociation with E12 or E47. 
Discussion 
We  demonstrate  dominant  negative  inhibition  of tetra- 
meric  [~-galactosidase  by  a  CB-IacZ fusion  polypeptide 
and  dimeric MyoD  by a  CB-MyoD  fusion  polypeptide. 
Substitution with two or more CB-fusion subunits  of the 
tetrameric 13-galactosidase inactivates enzymatic activity, 
as determined by titration experiments, and substitution of 
one subunit necessarily abrogates the transcriptional activ- 
ity of dimeric MyoD. At least in the case of 13-galactosi- 
dase, the inhibitor effect appears to result from a combina- 
tion  of subcellular  redistribution  to  lysosomal pathways 
and  direct proteolysis of the  holoenzyme by the  CB do- 
main.  Steric hindrance  of multimer assembly by the  CB 
domain appears negligible. It is perhaps surprising that a 
lysosomal protein should have the opportunity to associ- 
ate  with  a  protein  localized in  another  subcellular  com- 
partment, such as the cytoplasm or the nucleus. There are 
several  potential  reasons  why  our  method  nevertheless 
succeeds. First, it is likely that lysosomal trafficking is a dy- 
namic process and that proteins are continuously entering, 
and, possibly, exiting the lysosome through at least several 
different routes. Support for this is found in the observa- 
tions that some cell types have mannose-6-phosphate in- 
dependent  pathways to  the  lysosome (Owada  and  Neu- 
feld, 1982; Waheed et al., 1982; Rijnboutt et al., 1991), and 
some proteins, such as acid phosphatase, are routed to the 
lysosome independently of phosphorylation (Waheed et al., 
1988).  Second, under some circumstances, CB is found dif- 
fusely  localized  in  the  cytoplasm  (Amano  et  al.,  1995; 
Terada et  al.,  1995;  Campo et al.,  1994;  Visscher et  al., 
1994),  and not invariably in the lysosome, potentially in- 
creasing  the  likelihood  to  interact  with  other  proteins. 
Third, the gene fusions used in these experiments may re- 
sult in proteins with unusual patterns of subcellular local- 
ization. For example, the CB-MyoD construct, which con- 
tains both nuclear localization and lysosomal localization 
signals is obviously cytoplasmic, but from the staining pat- 
tern  the  precise  location  with  respect  to  the  lysosome, 
Golgi, ER,  and perinuclear region is unclear.  Therefore, 
the CB-fusion protein could conceivably cross paths at dif- 
ferent times with proteins trafficked to both the lysosome 
and the nucleus.  Fourth, the transfection conditions here 
likely result in supraphysiologic levels of expression, and it 
is possible that  the  usual  cellular compartments for CB- 
The Journal of Cell Biology, Volume 135, 1996  1054 I  I Illlll 
•  Illl llllllll  | 
0 tl  i  Illllllllllllll 
0tl I  I IIIIIllllllllll 
4R-~gal 11o  11o  lo  11o  11o  Ito  11o  11o  11o  11o 11o 
~"belsl  I  I  I  I  I  I  I  I  ~,,P,asmJOONA 
My°DI  I  ] S  I  S  I S  I S  I S  I  I  I  / perplateof 
E12-UyoD(~)  I  I  I  I  I  Islsls  JN~H3TaCe~ 
ca-~oO  I  pS  I  17.sltsl  I  I  1151 
CB'UyoDI  I  is  7.41511  ]15 
A  B  C  D  E  F  G  H  I  J  K 
Figure 8.  CB-MyoD  inhibits  trans-activation  of a  reporter by 
MyoD but not E12-MyoD(BJ). MyoD or E12-MyoD(BJ) fusion 
constructs  encoded in  EMSV-scribe  expression  vector (5  txg) 
were transiently cotransfected  into NIH 3T3 cells with plasmids 
expressing either CB-MyoD or the stop codon-containing  CB* 
MyoD control (7.5 or 5 Ixg of either) and 4R-13-gal reporter (10 I~g). 
Induction is normalized in each experiment by parallel cotrans- 
fection with 4R-13-gal reporter (10 Ixg) and the empty scribe vec- 
tor (5 Ixg) to which the ~-galactosidase activity is arbitrarily  as- 
signed a value of 1 (lane A). The reported 13-galactosidase activity 
for lanes B-K is thus expressed as a ratio of the activity for the 
conditions in lane A. 
lacZ, CB-MyoD, and NLS-IacZ (wherever they may be) 
have become saturated so that these polypeptides artifac- 
tually interact at sights within the cell where the cognate 
proteins are not normally found. While this suggests cau- 
tion in the interpretation of the biological relevance of our 
results, the pertinence of our findings is underscored by 
the experiments reported in Fig. 7 E, which demonstrate 
that CB-MyoDAC is, in fact, able to associate with endog- 
enous  MyoD  to  inhibit  differentiation in  C2C12  myo- 
blasts. 
We propose this approach as a simple and potentially 
general strategy for engineering dominant negative muta- 
tion. Like antisense, it may be suitable even in the absence 
of extensive structural  and functional knowledge of the 
protein to be studied, because the lysosomal localization 
signal in CB acts in c/s dominance to nuclear localization 
signals. It is possible that a dominant negative inhibitor for 
any protein can be manufactured simply by fusing the cod- 
ing sequence of the subject gene downstream from that of 
preprocathepsin B. A  specific application may be the con- 
struction  of fusion  cDNA  libraries  that  present  all  the 
cell's proteins as chimeras with CB. These libraries might 
allow for identification of genes by their ability to inhibit a 
particular activity. Although we  have not yet tested the 
dominance of lysosomal routing to other subcellular local- 
ization signals, in preliminary experiments with cDNA fu- 
sion libraries, we find that after screening several hundred 
epitope-tagged random clones comprised of a cDNA frag- 
ment fused to CB, almost all direct localization of the en- 
coded fusion protein is to the cytoplasm or, more specifi- 
cally,  the  lysosome.  This  suggests  that  the  lysosomal 
localization signal  possibly  acts  in  cis  dominance  to  all 
other subcellular localization signals. Another application 
may be in the development of "comtoxins" (Varshavsky, 
1995), drugs composed of two moieties: in this case, a lyso- 
somal  targeting  signal  fused  to  an  interaction  domain. 
Some  proteins,  in  addition  to  entering  the  lysosome 
cotranslationally within the cell, may enter the lysosome 
from the extracellular media through the cell surface via 
an  endosomal  route  (as  reviewed by Kornfeld and  Sly, 
1995). This  observation identifies a  potential means  for 
therapeutic delivery of an engineered polypeptide or small 
molecule through a  lysosomal cell surface receptor. This 
could be used, for example, to design a parenterally ad- 
ministerable  drug targeting the  destruction of a  cellular 
molecule, such as a particular membrane-bound receptor, 
through lysosomal sequestration. A different approach for 
designing dominant negative inhibitors in the absence of 
extensive structural and functional knowledge of the tar- 
geted protein is known as "genetic suppressor elements" 
(Roninson,  1995);  it  consists  of  randomly  fragmenting 
genes, expressing libraries of the sense strand, and select- 
ing the resulting oligopeptides capable of acting as domi- 
nant negative inhibitors. 
In our initial application of this strategy, we have inves- 
tigated the dimerization properties of MyoD. We find that 
CB-MyoD is an effective inhibitor of in vitro myoblast dif- 
ferentiation, and that this results from the specific inhibi- 
tion of MyoD's function as a transcriptional activator. We 
have previously reported that because MyoD is an auto- 
regulated protein, the steady-state level of MyoD is  ex- 
quisitely sensitive to small fluctuations in the half-life of 
the protein (Horwitz, 1996). Thus, even a small and tran- 
sient proteolytic destabilization of MyoD can impede dif- 
ferentiation by permanently switching off the MyoD auto- 
activation  circuit  and  the  cross-activation  circuits  with 
myogenin (as discussed in Horwitz, 1996). 
Surprisingly, the inhibitor effect does not appear to be 
mediated  through  heterodimerization with  E12  or  E47. 
There is no evidence for association between CB-MyoD with 
El2 or CB-E12 or CB-E47 with MyoD: CB-MyoD fails to 
inhibit trans-activation by a chimeric El2 substituted with 
the MyoD basic region, and CB-E12 and CB-E47 fail to 
inhibit myoblast differentiation. Despite our results, irre- 
futable evidence does support heterodimerization of MyoD 
with El2 or E47 (Lassar et al., 1991; Murre et al., 1989b): 
they can be coimmunoprecipitated; they associate and syn- 
ergistically bind DNA in gel shift experiments; and, they 
synergistically activate transcription of a  reporter. Addi- 
tionally, a covalently coupled heterodimer formed from a 
MyoD-E47 gene fusion is a potent activator, resistant to ti- 
tration by the endogenous, dominant negative inhibitor Id 
(Neuhold and Wold, 1993). 
In  performing immunoprecipitation  experiments, it  is 
possible that subcellular compartments become homoge- 
nized, while a potentially unique advantage of our studies 
may be  the  opportunity  to  observe  the  associations  of 
compartmentalized proteins in intact cells. Our data sup- 
port  the  unanticipated  possibility  that,  at  least  in  some 
compartments of the cytoplasm, MyoD more avidly homo- 
dimerizes  than  heterodimerizes.  A  possible  explanation 
for this preference could be that heterodimerization and 
nuclear transport are coupled, as has been proposed for 
the bHLH arylhydrocarbon receptor and  arnt dimeriza- 
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generally  for  other  bHLH  heterodimers  (Goldfarb  and 
Lewandowska, 1994). There is also evidence that hetero- 
dimerization is catalytically facilitated (Thayer and Wein- 
traub,  1993)  in a  process biochemically  dependent  upon 
phosphorylation (Lassar et al., 1991) or disulfide reduction 
(Benezra,  1994). Therefore, heterodimerization  might be 
regulated  through  many  means,  including  appropriate 
compartmentalization  of the  two factors  before  nuclear 
transport.  A  recent  report suggests  that  one  mechanism 
for accomplishing this may be through MyoD micelle for- 
mation (Laue et al., 1995). At least in solution, MyoD can 
form micelles  composed  of an  average  of ~120  MyoD 
molecules. Mixed micelles with E47 do not form, but the 
addition of E47 results in the stoichiometric formation of 
nonmicellar heterodimers. If micelle formation occurs in- 
tracellularly,  then  a  single  CB-MyoD  monomer  might 
have  an opportunity  to interact with hundreds  of native 
MyoD monomers, while it is relatively unlikely to interact 
with an E47 or El2 monomer (and vice-versa for CB-E12 
or CB-E47).  Our experiments provide no direct evidence 
for  micelle  formation,  but  they  are  consistent  with  the 
physical segregation of MyoD from its heterodimerization 
partners before nuclear transit. 
We caution that  some of the unique properties of our 
experimental conditions may limit the application of this 
method for other proteins. The autoregulation  of MyoD 
makes it exquisitely sensitive to small changes in its stabil- 
ity (Horwitz, 1996), and its possible potential to self-aggre- 
gate  in  large  complexes  could  potentiate  the  dominant 
negative effect. More specifically, as demonstrated  with 
13-galactosidase  and detailed in Fig. 3, the method is best 
suited for multimers with a large number of subunits (high q) 
and a poor tolerance for CB substituted subunits (low r). 
Since complete inhibition would likely seldom be possible, 
the method also requires that a measurable phenotype re- 
sult from moderate reductions in the level of the targeted 
protein. 
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